Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
67%
Ph not_applicable
1
17%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Completed2
Recruiting2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
N/A1 (16.7%)

Trials by Status

not_yet_recruiting117%
completed233%
active_not_recruiting117%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

NCT07715565
completedphase_1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

NCT03949153
active_not_recruitingphase_2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NCT03918252
completedphase_2

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

NCT05665348
recruitingnot_applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NCT06353646
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07715565Phase 2

Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

Not Yet Recruiting
NCT03949153Phase 1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

Completed
NCT03918252Phase 2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active Not Recruiting
NCT05665348Phase 2

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Completed
NCT06353646Not Applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Recruiting
NCT05428007Phase 2

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6